MabsSCIE

文章摘录

• Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity Author: Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2023.2180794
• High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions Author: Lourenco, Andre Luiz; Chuo, Shih-Wei; Bohn, Markus F.; Hann, Byron; Khan, Shireen; Yevalekar, Neha; Patel, Nitin; Yang, Teddy; Xu, Lina; Lv, Dandan; Drakas, Robert; Lively, Sarah; Craik, Charles S. Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2023.2184197
• Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer Author: Guan, Jiawei; Liu, Hongchuan; Chai, Yan; Yu, Jie; Yao, Jian; Wang, Jing; Pan, Zhiwei; Zhang, Jing; Zhou, Yuehua; Liu, Hui; Yao, Sheng; Qi, Jianxun; Feng, Hui; Gao, George. F. F.; Wang, Qihui; Shi, Yi; Tan, Shuguang Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2022.2153409
• Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. Author: Kuo WY¹, Hsu HJ¹, Wu CY², Chen HS¹, Chou YC¹, Tsou YL¹, Peng HP¹, Jian JW^1,3,4, Yu CM¹, Chiu YK¹, Chen IC¹, Tung CP¹, Hsiao M¹, Lin CL¹, Wang YA⁵, Wang AH⁶, Yang AS¹. Journal: MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
• Structure, heterogeneity and developability assessment of therapeutic antibodies. Author: Xu Y¹, Wang D², Mason B³, Rossomando T³, Li N⁴, Liu D⁵, Cheung JK⁶, Xu W⁷, Raghava S⁸, Katiyar A⁹, Nowak C³, Xiang T¹⁰, Dong DD¹⁰, Sun J¹¹, Beck A¹², Liu H³. Journal: MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17.
• De novo generation of specific human IgGs by in vitro immunization using autologous proteins containing immunogenic p-nitrophenylalanine. Author: Tong Y¹, Fang X¹, Tian H¹, Zhong S¹, Jin L¹, Gao X¹, Yao W¹. Journal: MAbs. 2019 Feb/Mar;11(2):401-410. doi: 10.1080/19420862.2018.1537580. Epub 2018 Dec 22.
• Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®. Author: Xu Y¹, Xie L¹, Zhang E¹, Gao W¹, Wang L¹, Cao Y¹, Xie MH¹, Jiang W¹, Liu S¹. Journal: MAbs. 2019 Apr;11(3):606-620. doi: 10.1080/19420862.2019.1578147. Epub 2019 Feb 22.
• Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. Author: Liu H¹, Guo L^2,3, Zhang J¹, Zhou Y¹, Zhou J¹, Yao J¹, Wu H¹, Yao S¹, Chen B¹, Chai Y⁴, Qi J⁴, Gao GF⁴, Tan S^2,4, Feng H¹, Yan J^2,3,4. Journal: MAbs. 2019 May/Jun;11(4):681-690. doi: 10.1080/19420862.2019.1596513. Epub 2019 Apr 19.